Patents Assigned to Cellectis SA
-
Publication number: 20250026808Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: ApplicationFiled: September 26, 2024Publication date: January 23, 2025Applicant: CELLECTIS SAInventors: Julianne SMITH, Phillippe DUCHATEAU, Murielle DERRIEN
-
Patent number: 12133867Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: GrantFiled: December 21, 2023Date of Patent: November 5, 2024Assignee: CELLECTIS SAInventors: Julianne Smith, Phillippe Duchateau, Murielle Derrien
-
Patent number: 11944643Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: GrantFiled: March 30, 2018Date of Patent: April 2, 2024Assignee: CELLECTIS SAInventors: Julianne Smith, Philippe Duchateau, Murielle Derrien
-
Patent number: 11690873Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: GrantFiled: March 30, 2018Date of Patent: July 4, 2023Assignee: CELLECTIS SAInventors: Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
-
Patent number: 11576317Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.Type: GrantFiled: November 13, 2020Date of Patent: February 14, 2023Assignees: CELLECTIS SA, MEDICAGO INC.Inventors: Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
-
Patent number: 11555198Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.Type: GrantFiled: October 31, 2013Date of Patent: January 17, 2023Assignees: CELLECTIS SA, MEDICAGO INC.Inventors: Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
-
Publication number: 20160304834Abstract: The present invention relates to the directed differentiation of mammalian pluripotent stem cells, especially human pluripotent stem (hPS) cells, into endodermal cells. In particular, the present invention relates to the treatment of mammalian pluripotent stem cells, especially hPS cells, with a DNA demethylating agent while undergoing differentiation into endodermal. The inventors have, as disclosed herein, found that exposing differentiating mammalian pluripotent stem cells, especially hPS cells, to a DNA demethylating agent leads to an improved morphology and improved yield of endodermal cells. The treatment with a DNA de-methylating agent also leads to a significant down-regulation of expression of the stem cell marker Oct4 and to an improved expression of endoderm specific markers, notably sox17, cxcr4 and hhex.Type: ApplicationFiled: November 28, 2013Publication date: October 20, 2016Applicant: CELLECTIS SAInventors: Barbara Küppers-Munther, Josefina Edsbagge
-
Patent number: 9044492Abstract: A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.Type: GrantFiled: February 6, 2012Date of Patent: June 2, 2015Assignee: CELLECTIS SAInventors: Fabien Delacote, Philippe Duchateau, Christophe Perez-Michaut
-
Publication number: 20140309145Abstract: The present invention relates to a method for the assembly and cloning of polynucleotides comprising highly similar polynucleotidic modules, that is highly versatile, does not require intermediate amplification step and can be easily automated for high throughput production of customized polynucleotidic modules.Type: ApplicationFiled: July 20, 2012Publication date: October 16, 2014Applicant: CELLECTIS SAInventors: Julien Valton, Alexandre Juillerat, Philippe Duchateau
-
Publication number: 20140120578Abstract: Materials and Methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.Type: ApplicationFiled: October 31, 2013Publication date: May 1, 2014Applicants: Medicago Inc., Cellectis SAInventors: Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-André D'Aoust
-
Publication number: 20120244131Abstract: A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.Type: ApplicationFiled: February 6, 2012Publication date: September 27, 2012Applicant: CELLECTIS SAInventors: Fabien Delacote, Philippe Duchateau, Christophe Perez-Michaut
-
Patent number: 7098031Abstract: The present invention concerns a method for in vivo generation of a linear polynucleotide with 5? and 3? free ends from a vector having no free end, said linear polynucleotide being integrated into the host cell genome. The vector having no free end according to the present invention comprise the polynucleotide to be linearized or excised flanked by a cleavage site, said cleavage site being preferably not found in the host cell genome. The present invention also relates to the resulting cells and their uses, for example for production of proteins or other genes, biomolecules, biomaterials, transgenic plants, vaccines, transgenic animals or for treatment or prophylaxis of a condition or disorder in an individual.Type: GrantFiled: September 13, 2002Date of Patent: August 29, 2006Assignee: Cellectis SAInventors: Andre Choulika, Jean-Stephane Joly, Violette Thermes, Filomena Ristoratore